Glimulin 2MF Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The prolonged-release formulation ensures a steady release of active ingredients, promoting better glycemic stability and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Glimulin 2MF Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal blood glucose levels. It is essential to monitor renal function prior to and during treatment, as metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. This medication should be used under medical supervision with appropriate lifestyle modifications, including diet and exercise, to maximize therapeutic outcomes in type 2 diabetes management. Regular monitoring of blood glucose and HbA1c is recommended to assess efficacy and adjust dosage accordingly.